Log in

NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price, Forecast & News

$3.18
-0.01 (-0.31 %)
(As of 02/18/2020 02:07 AM ET)
Today's Range
$3.12
Now: $3.18
$3.23
50-Day Range
$3.06
MA: $4.18
$5.15
52-Week Range
$2.52
Now: $3.18
$7.25
Volume2.86 million shs
Average Volume2.55 million shs
Market Capitalization$575.68 million
P/E Ratio4.61
Dividend YieldN/A
Beta3.1
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$0.60 per share

Profitability

Net Income$-53,120,000.00

Miscellaneous

Employees48
Market Cap$575.68 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.


ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.34. View ZIOPHARM Oncology's Earnings History.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for ZIOPHARM Oncology.

What price target have analysts set for ZIOP?

4 Wall Street analysts have issued 12-month price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $6.50 to $7.50. On average, they expect ZIOPHARM Oncology's stock price to reach $6.88 in the next twelve months. This suggests a possible upside of 116.2% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.

What is the consensus analysts' recommendation for ZIOPHARM Oncology?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology.

Has ZIOPHARM Oncology been receiving favorable news coverage?

News stories about ZIOP stock have trended extremely negative on Tuesday, according to InfoTrie. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for ZIOPHARM Oncology.

Who are some of ZIOPHARM Oncology's key competitors?

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Intrexon (XON), Celgene (CELG), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK), Arena Pharmaceuticals (ARNA) and Sarepta Therapeutics (SRPT).

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the folowing people:
  • Dr. Laurence James Neil Cooper, CEO & Director (Age 54)
  • Dr. David M. Mauney M.D., Pres (Age 50)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)
  • Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
  • Mr. David Connolly, VP of Corp. Communications & Investor Relations

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.28%), Charles Schwab Investment Management Inc. (0.55%), UBS Group AG (0.38%), Bank of New York Mellon Corp (0.38%), California Public Employees Retirement System (0.20%) and Vident Investment Advisory LLC (0.17%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View Institutional Ownership Trends for ZIOPHARM Oncology.

Which institutional investors are selling ZIOPHARM Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Rafferty Asset Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Creative Planning and New York State Common Retirement Fund. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include David M Md Mauney, Groot Eleanor De, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield. View Insider Buying and Selling for ZIOPHARM Oncology.

Which institutional investors are buying ZIOPHARM Oncology stock?

ZIOP stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, First Trust Advisors LP, California Public Employees Retirement System, UBS Asset Management Americas Inc., Bank of New York Mellon Corp, Vident Investment Advisory LLC, Virtus ETF Advisers LLC and Banque Cantonale Vaudoise. View Insider Buying and Selling for ZIOPHARM Oncology.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $3.18.

How big of a company is ZIOPHARM Oncology?

ZIOPHARM Oncology has a market capitalization of $575.68 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.View Additional Information About ZIOPHARM Oncology.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is http://www.ziopharm.com/.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]


MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  361 (Thanks for Voting!)
Underperform Votes:  392 (Thanks for Voting!)
Total Votes:  753
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Put Option

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel